Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SNS-595 · 4 trials · 4 indications
Objective tumor response rate based on the RECIST criteria for target lesions as assessed by CT or MRI: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD; Progressive Disease (PD), at least a 20% increase in the sum of the LD of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Overall Response (OR) = CR + PR
ORR is based on RECIST criteria to SNS-595 as a second-line therapy in patients with advanced NSCLC. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
| Arm | Type | Description |
|---|---|---|
| SNS-595 | EXPERIMENTAL | SNS-595; 48 mg/m2 administered IV once every 21 days for up to 6 cycles. |
| Treatment with 48 mg/m2 of SNS-595 | EXPERIMENTAL | Patients are treated with 48 mg/m2 of the drug SNS-595 injection once every 21 days for up to 6 cycles as a second -line therapy to patients with advanced non-small cell lung cancer (NSCLC) |
| Name | Type | Description |
|---|---|---|
| SNS-595 | DRUG | - |
| SNS-595 Injection | DRUG | Vosaroxin (formerly voreloxin or SNS-595) is a first in class anticancer quinolone derivative, non anthracycline topoisomerase II inhibitor. It induces replication dependent DNA damage by intercalating DNA and inhibiting topoisomerase II, leading to apoptosis. |
Inclusion Criteria: * Able to understand and willing to sign a written informed consent document * Patients who have recurrent or refractory SCLC requiring second-line chemotherapy who previously received first-line chemotherapy * Measurable disease * Eastern Cooperative Oncology Group (ECOG) Perfo...
SNS-595 is an investigational small molecule being studied for the treatment of solid tumors, including non-small-cell lung carcinoma and small cell lung cancer. It has been evaluated in clinical trials for patients with advanced non-small-cell lung cancer and small cell lung cancer.
SNS-595 is being developed by Viracta Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol VIRX. The company is conducting clinical research on this investigational oncology drug.
SNS-595 has completed Phase 2 clinical trials for the treatment of advanced non-small-cell lung cancer and small cell lung cancer. It is an investigational drug that has not been approved by regulatory authorities and remains in clinical development.
SNS-595 has been studied in two completed Phase 1 trials (NCT00091585 and NCT00094159) for solid tumors, and two completed Phase 2 trials: NCT00252382 for advanced non-small-cell lung cancer and NCT00298896 for small cell lung cancer.
No alternative names for SNS-595 have been disclosed in the available clinical trial information. The drug is identified solely by its code name SNS-595 in the registered studies.